Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis
Click the link to read a Mayo Clinic study entitled, “Safety and Efficacy of Intravesical Alum for Intractable Hemorrhagic Cystitis: A Contemporary Evaluation.” This study identified patients given intravesical alum between 1997 and 2014 for the treatment of HC. The researchers concluded:
“Intravesical alum instillation is associated with minimal morbidity and results in resolution of bleeding in approximately 60% of patients. Approximately one-third of patients maintain a durable response to treatment. Given its favorable safety/efficacy profile, intravesical alum should thereby be considered a first-line treatment option for patients with HC.”
Typically a challenging drug for hospitals to compound, Edge Pharma makes the process easy by offering a prefilled concentrated sterile alum solution. Learn more and setup an online ordering account for your hospital.